VENATORX PHARMACEUTICALS INC
MALVERN, Pennsylvania
Total Received
$315.8M
Total Awards
15
State
Pennsylvania
Last Updated
Mar 11, 2026
Yearly Funding Trend
$298.0M24
$10.4M25
$7.5M26
Top 15 Awards to VENATORX PHARMACEUTICALS INC
Largest individual federal awards on record for this recipient, ranked by obligated amount. Data through March 11, 2026.
| Award | Awarding Agency | Program | Place | FY | Obligation |
|---|---|---|---|---|---|
CONT_AWD_75A50119C00007_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES I.1 FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES, 52.204-14 SERVICES CONTRACT REPORTING REQUIREMENTS. | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | DOWNINGTOWN, PA-06 | 2024 | $107,189,039 |
CONT_AWD_75A50122C00080_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLES I.1 FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES, 52.204-14 SERVICES CONTRACT REPORTING REQUIREMENTS. | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | MALVERN, PA-06 | 2024 | $72,141,707 |
CONT_AWD_HHSN272201600029C_7529_-NONE-_-NONE- THE PURPOSE OF THIS CONTRACT IS THE DEVELOPMENT OF A NOVEL ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITOR THROUGH DELIVERY TO THE GOVERNMENT OF: CMC AND PRELIMINARY NON-CLINICAL DEV… | Department of Health and Human Services National Institutes of Health | — | MALVERN, PA-06 | 2024 | $48,773,739 |
CONT_AWD_75A50123C00050_7505_-NONE-_-NONE- THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE CLIN0005/OPTION 4, UPDATE ARTICLES G.3 KEY PERSONNEL, G.4.G CONTRACT FINANCIAL REPORT, G.8 POST AWARD EVALUATION OF CONTRACTOR PERF… | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | — | MALVERN, PA-06 | 2024 | $26,449,853 |
CONT_AWD_75N93020C00016_7529_-NONE-_-NONE- NON BETA-LACTAM INHIBITORS OF PENICILLIN BINDING PROTEINS TARGETING MDR-ACINETOBACTER BAUMANNII. | Department of Health and Human Services National Institutes of Health | — | MALVERN, PA-06 | 2024 | $25,044,893 |
ASST_NON_R01AI141239_075 NEW CLASS OF PBP INHIBITORS TO ADDRESS PBP2-MEDIATED RESISTANCE IN NEISSERIA GONORRHOEAE - PROJECT SUMMARY MULTIDRUG RESISTANT-GONORRHEA IS A SERIOUS GLOBAL HEALTH THREAT. PENICIL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2026 | $7,455,779 |
ASST_NON_R01AI136805_075 ESTABLISHING A GRAM-NEGATIVE PERMEATION RULE SET LEVERAGING A UNIQUE SMALL MOLECULE LIBRARY - ABSTRACT IT HAS BEEN MORE THAN 30 YEARS SINCE THE FIRST DESCRIPTIONS OF THE RELATION… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2025 | $7,356,765 |
ASST_NON_R01AI160269_075 NOVEL CYCLIC BORONATE PENICILLIN BINDING PROTEIN INHIBITORS TO ELIMINATE THE THREAT POSED BY Β-LACTAMASES AND ENABLE A FUTURE TREATMENT OPTION FOR CARBAPENEM-RESISTANT ENTEROBACTE… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $6,328,779 |
ASST_NON_R44AI170331_075 BROAD SPECTRUM Β-LACTAMASE INHIBITORS EMPLOYING A TROJAN HORSE MECHANISM TO RESCUE Β-LACTAMS AGAINST MULTIDRUG-RESISTANT PSEUDOMONAS AERUGINOSA - PROJECT SUMMARY: EVOLUTION OF MUL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $3,000,000 |
ASST_NON_R44AI155308_075 PRECLINICAL DEVELOPMENT OF CAPSID ASSEMBLY MODULATORS FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION - PROJECT SUMMARY DESPITE THE AVAILABILITY OF A SAFE AND EFFECTIVE V… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | PA-90 | 2025 | $3,000,000 |
ASST_NON_R44AI177015_075 OPTIMIZATION OF ORALLY BIOAVAILABLE INHIBITORS FOR THE TREATMENT OF COVID-19 AND OTHER HUMAN CORONAVIRUS INFECTIONS - PROJECT SUMMARY THE EMERGENCE OF SARS-COV-2 IN 2019 HAS RESUL… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $2,999,998 |
ASST_NON_R44AI118115_075 ADVANCEMENT OF ANTIVIRAL INHIBITORS OF CHIKUNGUNYA VIRUS - PROJECT SUMMARY NOVEL THERAPIES FOR THE TREATMENT OF CHIKUNGUNYA VIRUS (CHIKV) INFECTIONS ARE URGENTLY NEEDED TO ADDRESS… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $2,977,753 |
ASST_NON_R44AI181353_075 NOVEL CYCLIC BORONATE CELL WALL INHIBITORS TARGETING CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII - PROJECT SUMMARY Β-LACTAMS INCLUDING CARBAPENEMS ARE THE MOST WIDELY USED ANTIBI… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $2,000,000 |
ASST_NON_R43AI179443_075 DISCOVERY OF ANTIVIRAL INHIBITORS FOR THE TREATMENT OF ORTHOPOXVIRUS INFECTIONS - PROJECT SUMMARY SMALLPOX (CAUSED BY VARIOLA VIRUS INFECTION) WAS ONE OF THE MOST DESTRUCTIVE DISE… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $600,000 |
ASST_NON_R43AI157533_075 DISCOVERY OF INHIBITORS THAT TARGET HBX FOR THE TREATMENT OF CHRONIC HBV INFECTION - PROJECT SUMMARY THE HBV X PROTEIN (HBX) REPRESENTS AN ATTRACTIVE TARGET FOR DRUG DISCOVERY EFF… | Department of Health and Human Services National Institutes of Health | 93.855 ALLERGY AND INFECTIOUS DISEASES RESEARCH | MALVERN, PA-06 | 2024 | $506,216 |
Top 15 awards shown, ranked by obligated amount. Dates reflect performance period; last-modified dates match USAspending.gov. Complete listings include all transaction history going back to FY2024.
Funding Agencies
View All→Federal Programs (CFDA)
View All→Source: USAspending.gov · All Recipients · Pennsylvania